Intensity-Modulated Stereotactic Radiotherapy as an Upfront Scalp-Sparing Intervention for the Treatment of Newly Diagnosed Grade II-IV Gliomas
This phase II trial studies how well intensity-modulated stereotactic radiation therapy works in treating patients with grade II-IV glioma. Stereotactic radiosurgery is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may cause less damage to normal tissue.
• Patients must have histologically confirmed low or high grade glioma (grade II-IV)
• Karnofsky performance status (KPS) \>= 60
• Patients must have recovered from the effects of surgery; there must be a minimum of 21 days from the day of surgery to the day of protocol treatment
• Estimated survival \>= 3 months
• Labs considered acceptable per standard of care
• Patient must sign a study specific informed consent form
• Radiation treatment must begin \>= 3 weeks and =\< 8 weeks after surgery